Avatrombopag: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), NICE (England) and NYE METODER (Norway), among others, recommended or restricted avatrombopag, while AOTMIT (Poland) and CIPM (Spain) did not recommend it.
The record spans 2.8 years, opening at AWMSG (Wales) on 20 Mar 2020 and running to 15 Dec 2022.
SMC (Scotland) changed its position: recommended on 7 Dec 2020, restricted by 9 Aug 2021.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
7 distinct indication wordings are recorded for avatrombopag by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 17 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess avatrombopag, on 20 Mar 2020; PBAC (Australia) did not open a file until 2022 — a moderate spread of 2.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 17 dated records fall in 2021 alone.
Restriction is doing real work here: 3 of 11 decisive outcomes narrowed avatrombopag to a subgroup rather than accepting or refusing it outright, at NICE (England), SMC (Scotland) and TLV (Sweden).
5 of the 12 agencies here assessed avatrombopag more than once, NICE (England) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
avatrombopag has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for avatrombopag reads 5 recommended, 3 restricted, 3 not recommended and 3 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 15 Dec 2022 | NICE TA853 | recommended (optimised) | source |
| AWMSG (Wales) | 16 Nov 2022 | Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g… | outside AWMSG criteria | source |
| PBAC (Australia) | 2022 | Chronic immune (idiopathic) thrombocytopenia purpura | Recommended | source |
| AOTMIT (Poland) | 26 May 2022 | Doptelet reimbursement recommendation | not recommended | source |
| CIPM (Spain) | 3 Feb 2022 | Indicaciones terapéuticas autorizadas: Doptelet está indicado para el tratamiento de la trombocitopenia inmunitaria (TPI… | not financed by the SNS · art. 92 e | source |
12 further decisions for avatrombopag, across 10 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- lusutrombopag — divergent outcome (recommended vs no benefit) on a shared indication
- emicizumab — same ATC class B02B — Antihemorrhagics
- eltrombopag — same ATC class B02B — Antihemorrhagics
- romiplostim — same ATC class B02B — Antihemorrhagics
- concizumab — same ATC class B02B — Antihemorrhagics
- marstacimab — same ATC class B02B — Antihemorrhagics
Coverage: 17 decisions for avatrombopag from 12 agencies, 2020 to 2022. Data to 7 Sep 2026. ATC class B02B — Antihemorrhagics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.